Entyvio

Active Ingredient(s): Vedolizumab
FDA Approved: * May 19, 2014
Pharm Company: * TAKEDA PHARMS USA
Category: Gastrointestinal

Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc. for the treatment of ulcerative colitis and Crohn's disease.[3] It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7).[3][4] Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.[5]... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Entyvio 300 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 64764-300

Labeler:

Takeda Pharmaceuticals America, Inc.

Dosage List

Popular Topics